Therapeutic Potential of Induced and Natural FoxP3+ Regulatory T Cells for the Treatment of Graft-Versus-Host Disease



Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic stem-cell-transplantation. Present GvHD prophylaxis and treatment is still based on unspecific immunosuppressive drug therapy. Over the last decade, the potential of cell-based therapies involving the infusion of regulatory T cells has emerged as a feasible alternative approach for the treatment and prevention of GvHD. Here we review current efforts to translate data obtained in rodent models into clinical trials. Special emphasis is placed on the variety of strategies to generate sufficient numbers of alloantigen-specific regulatory T cells for adoptive cell therapy. This can be achieved either by expansion or by induction of a regulatory phenotype in naive T cells. Stability of the immunosuppressive phenotype of transferred regulatory T cells even in the highly inflammatory environment of acute GvHD will be thereby a critical parameter for actual therapeutic application.


GvHD Bone marrow transplantation FoxP3+ regulatory T cells 



This work was supported by grants from the Deutsche Forschungsgemeinschaft SFB621-A14 (I. Prinz), KO3582/3-1 (C. Koenecke) and Deutsche Krebshilfe No.109451 (C. Koenecke). We thank Andreas Krueger, Oliver Pabst and Anke Franzke for fruitful discussions and for critically reading the manuscript.


  1. Arimoto K, Kadowaki N, Ishikawa T et al (2007) FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 85:154–162PubMedCrossRefGoogle Scholar
  2. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105:4743–4748PubMedCrossRefGoogle Scholar
  3. Battaglia M, Stabilini A, Migliavacca B et al (2006) Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177:8338–8347PubMedGoogle Scholar
  4. Beres A, Komorowski R, Mihara M et al (2011) Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res 17:3969–3983PubMedCrossRefGoogle Scholar
  5. Brunstein CG, Miller JS, Cao Q et al (2011) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117:1061–1070PubMedCrossRefGoogle Scholar
  6. Cao J, Chen C, Zeng L et al (2010) Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Leuk Res 34:1374–1382PubMedCrossRefGoogle Scholar
  7. Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4+CD25 naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRefGoogle Scholar
  8. Chen X, Das R, Komorowski R et al (2009) Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114:891–900PubMedCrossRefGoogle Scholar
  9. Chen C, Cao J, Zeng L et al (2011) Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice. Transpl Proc 43:2041–2048CrossRefGoogle Scholar
  10. Coenen JJ, Koenen HJ, van Rijssen E et al (2006) Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107:1018–1023PubMedCrossRefGoogle Scholar
  11. Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30:626–635PubMedCrossRefGoogle Scholar
  12. Deeg HJ (2007) How I treat refractory acute GVHD. Blood 109:4119–4126PubMedCrossRefGoogle Scholar
  13. Deeg HJ, Spitzer TR, Cottler-Fox M et al (1991) Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transpl 7:193–198Google Scholar
  14. Di Ianni M, Falzetti F, Carotti A et al (2011) Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117:3921–3928PubMedCrossRefGoogle Scholar
  15. Dominguez-Villar M, Baecher-Allan CM, Hafler DA (2011) Identification of T helper type 1-like, Foxp3(+) regulatory T cells in human autoimmune disease. Nat Med 17:673–675PubMedCrossRefGoogle Scholar
  16. Duarte JH, Zelenay S, Bergman ML et al (2009) Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 39:948–955PubMedCrossRefGoogle Scholar
  17. Edinger M, Hoffmann P, Ermann J et al (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144–1150PubMedCrossRefGoogle Scholar
  18. Esposito M, Ruffini F, Bergami A et al (2010) IL-17- and IFN-gamma-secreting Foxp3+ T cells infiltrate the target tissue in experimental autoimmunity. J Immunol 185:7467–7473PubMedCrossRefGoogle Scholar
  19. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336PubMedCrossRefGoogle Scholar
  20. Gershon RK, Kondo K (1971) Infectious immunological tolerance. Immunology 21:903–914PubMedGoogle Scholar
  21. Godfrey WR, Ge YG, Spoden DJ et al (2004) In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104:453–461PubMedCrossRefGoogle Scholar
  22. Golovina TN, Mikheeva T, Suhoski MM et al (2008) CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 181:2855–2868PubMedGoogle Scholar
  23. Golshayan D, Jiang S, Tsang J et al (2007) In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 109:827–835PubMedCrossRefGoogle Scholar
  24. Hippen KL, Harker-Murray P, Porter SB et al (2008) Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112:2847–2857PubMedCrossRefGoogle Scholar
  25. Hippen KL, Merkel SC, Schirm DK, et al (2011) Massive ex vivo expansion of human natural regulatory T Cells (Tregs) with minimal loss of in vivo functional activity. Sci Transl Med 3:83ra41Google Scholar
  26. Hoffmann P, Ermann J, Edinger M et al (2002) Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196:389–399PubMedCrossRefGoogle Scholar
  27. Hoffmann P, Eder R, Kunz-Schughart LA et al (2004) Large-scale in vitro expansion of polyclonal human CD4(+)CD25 high regulatory T cells. Blood 104:895–903PubMedCrossRefGoogle Scholar
  28. Hoffmann P, Boeld TJ, Eder R et al (2006) Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transpl 12:267–274CrossRefGoogle Scholar
  29. Hoffmann P, Boeld TJ, Eder R et al (2009) Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 39:1088–1097PubMedCrossRefGoogle Scholar
  30. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRefGoogle Scholar
  31. Jiang S, Camara N, Lombardi G et al (2003) Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 102:2180–2186PubMedCrossRefGoogle Scholar
  32. Jiang A, Bloom O, Ono S et al (2007) Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 27:610–624PubMedCrossRefGoogle Scholar
  33. Karakhanova S, Munder M, Schneider M et al (2006) Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J Immunother 29:336–349PubMedCrossRefGoogle Scholar
  34. Khattar M, Chen W, Stepkowski SM (2009) Expanding and converting regulatory T cells: a horizon for immunotherapy. Arch Immunol Ther Exp 57:199–204CrossRefGoogle Scholar
  35. Khattri R, Cox T, Yasayko SA et al (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337–342PubMedCrossRefGoogle Scholar
  36. Kingsley CI, Karim M, Bushell AR et al (2002) CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 168:1080–1086PubMedGoogle Scholar
  37. Koenecke C, Czeloth N, Bubke A et al (2009) Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 39:3091–3096PubMedCrossRefGoogle Scholar
  38. Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112:4371–4383PubMedCrossRefGoogle Scholar
  39. Komatsu N, Mariotti-Ferrandiz ME, Wang Y et al (2009) Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 106:1903–1908PubMedCrossRefGoogle Scholar
  40. Koreth J, Matsuoka K, Kim HT et al (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055–2066PubMedCrossRefGoogle Scholar
  41. Kroger N, Zabelina T, Kruger W et al (2002) In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transpl 29:683–689CrossRefGoogle Scholar
  42. Levings MK, Sangregorio R, Roncarolo MG (2001) Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295–1302PubMedCrossRefGoogle Scholar
  43. Lin CH, Hunig T (2003) Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 33:626–638PubMedCrossRefGoogle Scholar
  44. Liu YJ, Wu DP, Li CX et al (2006) The role of CD4+CD25+ T cell and FOXP3 in hsot acute graft rejection. Zhonghua Nei Ke Za Zhi 45:835–838PubMedGoogle Scholar
  45. Lord JD, Hackman RC, Gooley TA et al (2011) Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease. Biol Blood Marrow Transpl 17:486–496CrossRefGoogle Scholar
  46. Magenau JM, Qin X, Tawara I et al (2010) Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. B. Biol Blood Marrow Transpl 16:907–914CrossRefGoogle Scholar
  47. McMurchy AN, Bushell A, Levings MK et al (2011) Moving to tolerance: clinical application of T regulatory cells. Semin Immunol 23:304–313PubMedCrossRefGoogle Scholar
  48. Mielcarek M, Martin PJ, Leisenring W et al (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102:756–762PubMedCrossRefGoogle Scholar
  49. Mielke S, Rezvani K, Savani BN et al (2007) Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110:1689–1697PubMedCrossRefGoogle Scholar
  50. Miura Y, Thoburn CJ, Bright EC et al (2004) Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104:2187–2193PubMedCrossRefGoogle Scholar
  51. Miyara M, Sakaguchi S (2011) Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol 89:346–351PubMedCrossRefGoogle Scholar
  52. Murai M, Krause P, Cheroutre H et al (2010) Regulatory T-cell stability and plasticity in mucosal and systemic immune systems. Mucosal Immunol 3:443–449PubMedCrossRefGoogle Scholar
  53. Nguyen VH, Shashidhar S, Chang DS et al (2008) The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 111:945–953PubMedCrossRefGoogle Scholar
  54. Oldenhove G, Bouladoux N, Wohlfert EA et al (2009) Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31:772–786PubMedCrossRefGoogle Scholar
  55. Petersdorf EW, Gooley T, Malkki M et al (2007) Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 69(Suppl 1):25–30PubMedCrossRefGoogle Scholar
  56. Pidala J, Anasetti C, Jim H (2009) Quality of life after allogeneic hematopoietic cell transplantation. Blood 114:7–19PubMedCrossRefGoogle Scholar
  57. Platzbecker U, Ehninger G, Bornhauser M (2004) Allogeneic transplantation of CD34+ selected hematopoietic cells—clinical problems and current challenges. Leuk Lymphoma 45:447–453PubMedCrossRefGoogle Scholar
  58. Putnam AL, Brusko TM, Lee MR et al (2009) Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58:652–662PubMedCrossRefGoogle Scholar
  59. Ratanatharathorn V, Nash RA, Przepiorka D et al (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303–2314PubMedGoogle Scholar
  60. Rubtsov YP, Niec RE, Josefowicz S et al (2010) Stability of the regulatory T cell lineage in vivo. Science 329:1667–1671PubMedCrossRefGoogle Scholar
  61. Sakaguchi S, Sakaguchi N, Asano M et al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164PubMedGoogle Scholar
  62. Schraven B, Kalinke U (2008) CD28 superagonists: what makes the difference in humans? Immunity 28:591–595PubMedCrossRefGoogle Scholar
  63. Sela U, Olds P, Park A et al (2011) Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice. J Exp Med 208:2489–2496PubMedCrossRefGoogle Scholar
  64. Shin HJ, Baker J, Leveson-Gower DB et al (2011) Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118:2342–2350PubMedCrossRefGoogle Scholar
  65. Socie G, Blazar BR (2009) Acute graft-versus-host disease: from the bench to the bedside. Blood 114:4327–4336PubMedCrossRefGoogle Scholar
  66. Strauss L, Whiteside TL, Knights A et al (2007) Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178:320–329PubMedGoogle Scholar
  67. Taylor PA, Noelle RJ, Blazar BR (2001) CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193:1311–1318PubMedCrossRefGoogle Scholar
  68. Taylor PA, Lees CJ, Blazar BR (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99:3493–3499PubMedCrossRefGoogle Scholar
  69. Tran DQ, Andersson J, Hardwick D et al (2009) Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 113:5125–5133PubMedCrossRefGoogle Scholar
  70. Trenado A, Charlotte F, Fisson S et al (2003) Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112:1688–1696PubMedGoogle Scholar
  71. Trzonkowski P, Bieniaszewska M, Juscinska J et al (2009) First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127 T regulatory cells. Clin Immunol 133:22–26PubMedCrossRefGoogle Scholar
  72. Tu W, Lau YL, Zheng J et al (2008) Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood 112:2554–2562PubMedCrossRefGoogle Scholar
  73. Ukena SN, Grosse J, Mischak-Weissinger E et al (2011a) Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/−) regulatory T cells. Ann Hematol 90:213–218PubMedCrossRefGoogle Scholar
  74. Ukena SN, Velaga S, Geffers R et al (2011b) Human regulatory T cells in allogeneic stem cell transplantation. Blood 118:e82–e92PubMedCrossRefGoogle Scholar
  75. Ukena SN, Hopting M, Velaga S et al (2011c) Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. Exp Hematol 39:1152–1160PubMedCrossRefGoogle Scholar
  76. Wagner JE, Thompson JS, Carter SL et al (2005) Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial. Lancet 366:733–741PubMedCrossRefGoogle Scholar
  77. Wang ZD, Feng SZ, Zhou SY et al (2006) Difference between FOXP3 gene expressions in donor grafts with or without acute graft-versus-host disease. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14:1215–1220PubMedGoogle Scholar
  78. Wood KJ, Hara M, Kingsley CI et al (2001) Immunoregulatory T-cells can mediate specific unresponsiveness to alloantigens in vivo. Transpl Proc 33:3829–3830CrossRefGoogle Scholar
  79. Yamazaki S, Iyoda T, Tarbell K et al (2003) Direct expansion of functional CD25+CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198:235–247PubMedCrossRefGoogle Scholar
  80. Yamazaki S, Patel M, Harper A et al (2006) Effective expansion of alloantigen-specific Foxp3+CD25+CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA 103:2758–2763PubMedCrossRefGoogle Scholar
  81. Zhou X, Bailey-Bucktrout SL, Jeker LT et al (2009) Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10:1000–1007PubMedCrossRefGoogle Scholar
  82. Zorn E, Nelson EA, Mohseni M et al (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108:1571–1579PubMedCrossRefGoogle Scholar
  83. Zorn E, Mohseni M, Kim H et al (2009) Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 15:382–388CrossRefGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2012

Authors and Affiliations

  1. 1.Institute of ImmunologyHannover Medical SchoolHannoverGermany
  2. 2.Department of Hematology, Hemostasis, Oncology and Stem-Cell TransplantationHannover Medical SchoolHannoverGermany

Personalised recommendations